| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
2-Chloro-5-cyanopyridine exhibits high inhibition against acetylcholinesterase and butyrylcholinesterase enzymes. It has also been shown to have potent inhibitory activity on hematopoietic cells and chaperone proteins. The inhibition of cyclic AMP phosphodiesterase by 2,4-diamino-5-cyano-6-halopyridines suggests potential in treating conditions such as diabetes and asthma. The compound's intracellular levels are highest when dechlorinated, which may be due to its high chemical stability and low reactivity with other molecules. The compound interacts with various enzymes, proteins, and other biomolecules.
|
|---|---|
| ln Vitro |
In vitro, 2-chloro-5-cyanopyridine has demonstrated high inhibition against acetylcholinesterase and butyrylcholinesterase enzymes. It has potent inhibitory activity on hematopoietic cells and chaperone proteins. The compound is used as a biochemical reagent in life science research. It is employed in the preparation of various chemical intermediates. The compound's activity against cholinesterases suggests potential therapeutic applications in neurological conditions. Cellular assays typically evaluate its enzyme inhibition activity.
|
| ln Vivo |
In vivo data for 2-chloro-5-cyanopyridine is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. The inhibition of cyclic AMP phosphodiesterase by related compounds suggests potential for treating conditions such as diabetes and asthma. The compound's potent inhibition of cholinesterases suggests potential neurological applications. Specific in vivo data for the parent compound is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme assays for 2-chloro-5-cyanopyridine typically evaluate its activity against acetylcholinesterase, butyrylcholinesterase, and other enzymes. A standard assay protocol involves incubating the compound with purified enzymes in appropriate buffer systems containing the substrate. The compound is dissolved in DMSO and diluted to working concentrations (typically 0.1 nM to 100 μM). Enzyme activity is measured by quantifying substrate hydrolysis or product formation using colorimetric or fluorometric methods. IC₅₀ values are calculated from dose-response curves. The compound's binding to enzymes can also be evaluated using competitive binding assays.
|
| Cell Assay |
Cellular assays for 2-chloro-5-cyanopyridine typically evaluate its enzyme inhibition activity and effects on cell function. A standard protocol involves culturing appropriate cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound (typically 0.1-100 μM) for 24-72 hours. Enzyme activity is measured in cell lysates using appropriate substrates. Cell viability is assessed using MTT or similar assays. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for 2-chloro-5-cyanopyridine are not standard, as it is a research reagent rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies involving this compound would typically be conducted on the final pharmaceutical products synthesized using this building block rather than on the building block itself. The compound's primary value lies in its use as a synthetic intermediate.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2-chloro-5-cyanopyridine is limited, as it is primarily a research reagent. The compound has a molecular weight of 138.55 g/mol. It is stored as a solid at -20°C for long-term stability. As a chloropyridine, the compound may undergo metabolic dechlorination and nitrile hydrolysis. The compound's high chemical stability may influence its pharmacokinetic properties. Specific ADME data is not available in the public literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-chloro-5-cyanopyridine is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
2-Chloro-5-cyanopyridine (CAS 33252-28-7) is a biochemical reagent with the molecular formula C₆H₃ClN₂. It exhibits high inhibition against acetylcholinesterase and butyrylcholinesterase enzymes. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis.
|
| Molecular Formula |
C6H3CLN2
|
|---|---|
| Molecular Weight |
138.55
|
| Exact Mass |
152.014
|
| CAS # |
33252-28-7
|
| PubChem CID |
5152094
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
294.1±25.0 °C at 760 mmHg
|
| Melting Point |
116-120 °C(lit.)
|
| Flash Point |
131.7±23.2 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
0.63
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
137
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=NC(=C1)Cl)C#N
|
| InChi Key |
ORIQLMBUPMABDV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H3ClN2/c7-6-2-1-5(3-8)4-9-6/h1-2,4H
|
| Chemical Name |
6-chloropyridine-3-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2176 mL | 36.0881 mL | 72.1761 mL | |
| 5 mM | 1.4435 mL | 7.2176 mL | 14.4352 mL | |
| 10 mM | 0.7218 mL | 3.6088 mL | 7.2176 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
